Cingulate Inc. (CING)

US — Healthcare Sector
Peers:   SABSW  SNTI  BLCM  HILS  AVTE  ADAG  ACRV  RZLT  ANTX  GNLX  CMRA  DYAI  MNPR  MIRO  IKT  PMVP  ANEB 

Automate Your Wheel Strategy on CING

With Tiblio's Option Bot, you can configure your own wheel strategy including CING - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CING
  • Rev/Share 0.0
  • Book/Share 3165.9525
  • PB 0.0024
  • Debt/Equity 0.0056
  • CurrentRatio 1.8709
  • ROIC -0.9544

 

  • MktCap 16643195.0
  • FreeCF/Share -1266.3156
  • PFCF -0.0036
  • PE -0.002
  • Debt/Assets 0.0027
  • DivYield 0
  • ROE -4.7325

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CING ROTH MKM -- Buy -- $12 Jan. 10, 2025

News

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
CING
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission

Read More
image for news Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

About Cingulate Inc. (CING)

  • IPO Date 2021-12-08
  • Website https://www.cingulate.com
  • Industry Biotechnology
  • CEO Dr. Shane J. Schaffer Pharm.D.
  • Employees 13

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.